Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, moves that triggered a sharp selloff in the stock.

See our latest analysis for Myriad Genetics.

For investors tracking Myriad Genetics over a longer horizon, the recent earnings miss and lower 2026 revenue guidance have accelerated an already weak trend. The 1-day share price return of down 46.74% adds to a year-to-date share price decline of 53.42% and a 5-year total shareholder return decline of 91.70%. This points to fading momentum and a market that is reassessing the company's risk profile despite partnership announcements such as the expanded HRD collaboration with Burning Rock Biotech.

If this kind of sharp move has you reassessing your watchlist, it could be a useful moment to see what else is happening across cancer and diagnostics by checking 41 healthcare AI stocks

After a 46% one day drop and a 5 year shareholder return decline of 91.70%, Myriad Genetics now sits at a fraction of its past value. Is most of the reset already priced in, or is the potential upside from here still limited?

Most Popular Narrative: 54.2% Undervalued

The most followed valuation narrative for Myriad Genetics puts fair value at $6.25 per share, compared with the last close of $2.86. That gap reflects a view that the current price does not fully reflect the company's long term revenue and margin potential.

The company is accelerating growth in its oncology business by expanding beyond hereditary cancer testing into comprehensive genomic profiling, immuno oncology response monitoring, and MRD (minimal residual disease), leveraging its established reputation with healthcare providers. This product and market expansion is likely to increase the company's addressable market, supporting long term revenue growth.

Read the complete narrative.

Want to see how that oncology push, planned margin lift, and future earnings profile fit together? The narrative walks through a full set of revenue, profitability and valuation assumptions that sit behind the $6.25 figure.

Result: Fair Value of $6.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh reimbursement pushback around tests like GeneSight and higher interest costs from the US$200 million OrbiMed loan, which could put pressure on Myriad Genetics.